Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Share price

<< Previous

Bullboard Posts

Next >>

Comment by Snowballgrowthon Aug 08, 2021 1:01pm

145 Views

Post# 33669581

RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price

MrMugsy wrote:

Snowballgrowth wrote:

MrMugsy wrote:

Snowballgrowth wrote:

EbbFlow88 wrote: It also seems like someone else is accumulating GUD. Big chunks of stock being bought the last 3 days

I guess we should get more info next week. We need to see growth and better margins

Remember - attitudes and the make-up of shareholders really isn't going to change much until we see this going to $12-$15 ... until then it will continue to be tightly held with very few new entrants. Once we get there ... likely showing good growth and ROW is happening for a new investor base to hop on. IMO.

My comment wasn't about stock price or "" sentiment"", it was about GUD's financials results.

True Snowball - I think I accidently quoted the wrong comment when made my comment about when we likely see a change in the shareholder base and an interest in the shares. Sorry about that.